NEW YORK, Aug. 22, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Ardelyx, Inc. (NASDAQ: ARDX).Shareholders who purchased shares of ARDX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/ardelyx-loss-submission-form/?id=97082&from=4CLASS PERIOD: October 31, 2023 to July 1, 2024 ...

NEW YORK, Aug. 21, 2024 /PRNewswire/ --Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of all purchasers of securities of Ardelyx, Inc. (NASDAQ: ARDX) between October 31, 2023 and July 1, 2024, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 15, 2024.So What: If you purchased Ardelyx securities during the Class Period ...

LOS ANGELES, Aug. 21, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ardelyx, Inc. (“Ardelyx” or “the Company”) (NASDAQ: ARDX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company’s securities between October 31, 2023 and July 1, 2024, inclusive (the “Class Period”), ar ...

NEW YORK, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Ardelyx, Inc. (“Ardelyx” or the “Company”) (NASDAQ: ARDX) in the United States District Court for the District of Massachusetts on behalf of all persons and entities who purchased or otherwise acquired Ardelyx securities between October 31, 2023 and July 1, 2024, both dates inclusive (the “Class Period”). Investors have unt ...

NEW YORK, Aug. 20, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of all purchasers of securities of Ardelyx, Inc. (NASDAQ: ARDX) between October 31, 2023 and July 1, 2024, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 15, 2024. SO WHAT: If you purchased Ardelyx securities during the Class ...

ATLANTA, Aug. 19, 2024 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed Ardelyx, Inc. (“Ardelyx” or the “Company”) (NASDAQ: ARDX). The lawsuit alleges that Defendants indicated that Ardelyx would apply to include its product, XPHOZAH, in the Transitional Drug Add-on Payment Adjustment (“TDAPA”) when, in fact, Ardelyx had not yet reached a firm decision concerning whether or not to apply to include XPHOZAH in TDAPA, and could not, in fact, decide whether or not to submit such an applicat ...

SAN DIEGO, Aug. 18, 2024 (GLOBE NEWSWIRE) -- Robbins LLP informs investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Ardelyx, Inc. (NASDAQ: ARDX) securities between October 31, 2023 and July 1, 2024. Ardelyx is a biotechnology company focused on developing and commercializing therapies for, among other things, patients with chronic kidney disease (“CKD”). For more information, submit a form, email attorney Aaron Dumas, Jr., or give us ...

Ardelyx, Inc. (NASDAQ:ARDX) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ET Company Participants Caitlin Lowie - Vice President of Corporate Communications & Investor Relations Michael Raab - President & Chief Executive Officer Susan Rodriguez - Chief Commercial Officer Justin Renz - Chief Financial Officer & Chief Operations Officer Conference Call Participants Louise Chen - Cantor Fitzgerald Yigal Nochomovitz - Citi Dennis Ding - Jefferies Laura Chico - Wedbush Roanna Ruiz - Leerink Partners Ry ...

Ardelyx (ARDX) reported $73.22 million in revenue for the quarter ended June 2024, representing a year-over-year increase of 227.9%. EPS of -$0.07 for the same period compares to -$0.08 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $55.73 million, representing a surprise of +31.38%. The company delivered an EPS surprise of +30.00%, with the consensus EPS estimate being -$0.10.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and ...

Ardelyx (ARDX) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.08 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 30%. A quarter ago, it was expected that this biotechnology company would post a loss of $0.13 per share when it actually produced a loss of $0.11, delivering a surprise of 15.38%.Over the last four quarters, the company has surpa ...